New hope for brittle bones: experimental drug enters phase 2 trial in china
NCT ID NCT07557446
First seen May 06, 2026 · Last updated May 15, 2026 · Updated 2 times
Summary
This study tests an experimental drug called AGA2115 in 48 Chinese adults and adolescents with types I, III, or IV osteogenesis imperfecta (brittle bone disease). The goal is to find the best dose and check for side effects, while also measuring changes in bone density over 12 months. Participants must have a confirmed genetic diagnosis and low bone density to join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOGENESIS IMPERFECTA (OI) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Soochow University
Suzhou, Jiangsu, 215025, China
Contact
-
Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100005, China
Contact
-
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, 200233, China
Contact
-
The University of Hong Kong-Shenzhen Hospital
Shenzhen, Guangdong, 518053, China
Contact
Conditions
Explore the condition pages connected to this study.